Matthew Ulrickson, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Travel
    Ineligible company: 
    Miltenyi
    Topic: 
    zamtocabtagene
    Date added: 
    07/18/2023
    Relationship end date: 
    06/17/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Gilead
    Topic: 
    MDS
    Date added: 
    07/18/2023
    Relationship end date: 
    03/04/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Bristol Meyers Squib
    Topic: 
    AML
    Date added: 
    07/18/2023
    Relationship end date: 
    02/11/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Stemline
    Topic: 
    BPDCN
    Date added: 
    07/18/2023
    Relationship end date: 
    07/30/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Genetech
    Topic: 
    AML
    Date added: 
    07/18/2023
    Relationship end date: 
    05/27/2023
Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes